WO2001014579A3 - Compositions et procedes pour la delivrance d'un agent par le biais d'une salmonelle attenuee contenant un phage - Google Patents

Compositions et procedes pour la delivrance d'un agent par le biais d'une salmonelle attenuee contenant un phage Download PDF

Info

Publication number
WO2001014579A3
WO2001014579A3 PCT/US2000/023243 US0023243W WO0114579A3 WO 2001014579 A3 WO2001014579 A3 WO 2001014579A3 US 0023243 W US0023243 W US 0023243W WO 0114579 A3 WO0114579 A3 WO 0114579A3
Authority
WO
WIPO (PCT)
Prior art keywords
agent
delivery
compositions
methods
bacteriophage
Prior art date
Application number
PCT/US2000/023243
Other languages
English (en)
Other versions
WO2001014579A9 (fr
WO2001014579A2 (fr
Inventor
David G Bermudes
Ivan C King
Caroline A Clairmont
Original Assignee
Vion Pharmaceuticals Inc
David G Bermudes
Ivan C King
Caroline A Clairmont
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vion Pharmaceuticals Inc, David G Bermudes, Ivan C King, Caroline A Clairmont filed Critical Vion Pharmaceuticals Inc
Priority to AU75729/00A priority Critical patent/AU7572900A/en
Priority to CA002381755A priority patent/CA2381755A1/fr
Publication of WO2001014579A2 publication Critical patent/WO2001014579A2/fr
Publication of WO2001014579A3 publication Critical patent/WO2001014579A3/fr
Publication of WO2001014579A9 publication Critical patent/WO2001014579A9/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne, d'une manière générale, la délivrance d'un agent thérapeutique ou prophylactique, et plus particulièrement la préparation et l'utilisation d'une bactérie atténuée, du type salmonelle, contenant un bactériophage dont on a modifié le génome pour coder un produit génique visé, du type antigène ou protéine antitumorale. La bactérie tient lieu de vecteur, pour la délivrance du produit génique visé - qui est codé par le bactériophage - sur un site d'action approprié, du type site de tumeur solide.
PCT/US2000/023243 1999-08-26 2000-08-24 Compositions et procedes pour la delivrance d'un agent par le biais d'une salmonelle attenuee contenant un phage WO2001014579A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU75729/00A AU7572900A (en) 1999-08-26 2000-08-24 Compositions and methods for delivery of an agent using attenuated salmonella containing phage
CA002381755A CA2381755A1 (fr) 1999-08-26 2000-08-24 Compositions et procedes pour la delivrance d'un agent par le biais d'une salmonelle attenuee contenant un phage

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15092899P 1999-08-26 1999-08-26
US60/150,928 1999-08-26

Publications (3)

Publication Number Publication Date
WO2001014579A2 WO2001014579A2 (fr) 2001-03-01
WO2001014579A3 true WO2001014579A3 (fr) 2001-10-25
WO2001014579A9 WO2001014579A9 (fr) 2002-09-19

Family

ID=22536590

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/023243 WO2001014579A2 (fr) 1999-08-26 2000-08-24 Compositions et procedes pour la delivrance d'un agent par le biais d'une salmonelle attenuee contenant un phage

Country Status (4)

Country Link
US (2) US20030113293A1 (fr)
AU (1) AU7572900A (fr)
CA (1) CA2381755A1 (fr)
WO (1) WO2001014579A2 (fr)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010112944A (ko) * 1999-04-21 2001-12-22 이곤 이 버그 폴리뉴클레오티드 서열의 기능을 억제하기 위한 방법 및조성물
US20040138168A1 (en) * 1999-04-21 2004-07-15 Wyeth Methods and compositions for inhibiting the function of polynucleotide sequences
WO2001014579A2 (fr) * 1999-08-26 2001-03-01 Vion Pharmaceuticals, Inc. Compositions et procedes pour la delivrance d'un agent par le biais d'une salmonelle attenuee contenant un phage
US20020054865A1 (en) * 2000-09-21 2002-05-09 Minoru Fujimori Anaerobic bacterium as a drug for cancer gene therapy
GB0107319D0 (en) * 2001-03-23 2001-05-16 Moredun Res Inst Bacteriophage-mediated immunisation
US6759229B2 (en) 2001-12-18 2004-07-06 President & Fellows Of Harvard College Toxin-phage bacteriocide antibiotic and uses thereof
CA2477675C (fr) * 2002-03-05 2013-05-21 Ramot At Tel-Aviv University Ltd. Composition immunisante et procede permettant d'induire une reponse immunitaire contre le site de clivage de .beta.-secretase de la proteine du precurseur de l'amyloide
GB0222824D0 (en) * 2002-10-02 2002-11-06 Moredun Res Inst Bacteriophage-mediated immunisation II
CN100562570C (zh) 2003-06-18 2009-11-25 吉恩勒克斯公司 修饰的重组痘苗病毒及其它微生物,及其应用
ES2260985B1 (es) * 2003-12-04 2007-11-01 Universidad Pablo De Olavide Procedimiento de regulacion de la expresion de proteinas heterologas controladas por derivados salicilicos en microorganismos asociados a organismos superiores.
JP2008504822A (ja) * 2004-06-29 2008-02-21 アンチキャンサー インコーポレーテッド 癌選択的栄養要求株
DK1812025T3 (da) * 2004-11-02 2012-10-22 Chr Hansen As Stabiliserede bakteriofagformuleringer
DK2088193T3 (da) 2004-11-24 2011-02-28 Anaeropharma Science Inc Ny shuttle-vektor
CA2593992A1 (fr) * 2004-12-06 2006-06-15 Rodney M. Donlan Inhibition de la formation de biofilm par un bacteriophage
CA2775655C (fr) * 2005-01-20 2014-03-25 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Analyse multiplexee pour l'etablissement d'un serodiagnostic d'une infection virale
CN1330758C (zh) 2005-01-21 2007-08-08 四川大学 抗真菌多肽及其制备方法
US8734779B2 (en) * 2005-04-08 2014-05-27 Anaeropharma Science Inc. 5-fluorouracil-resistant bacteria and method for production thereof
WO2007027338A2 (fr) * 2005-07-29 2007-03-08 Amyris Biotechnologies, Inc. Biosynthese et delivrance de composes therapeutiques
EP1764107A1 (fr) * 2005-09-14 2007-03-21 Gunther Hartmann Compositions comportant les oligonucléotides d'ARN immunostimulatoire et les méthodes pour produire lesdits oligonucléotides d'ARN
US20080124355A1 (en) * 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
WO2009126189A1 (fr) 2008-01-11 2009-10-15 Genelux Corporation Procédés et compositions pour la détection de bactéries et le traitement de maladies et de troubles
US8647642B2 (en) 2008-09-18 2014-02-11 Aviex Technologies, Llc Live bacterial vaccines resistant to carbon dioxide (CO2), acidic PH and/or osmolarity for viral infection prophylaxis or treatment
WO2010051820A1 (fr) * 2008-11-10 2010-05-14 Aarhus Universitet Vaccination contre multiplexée par la cytokine
US8241623B1 (en) 2009-02-09 2012-08-14 David Bermudes Protease sensitivity expression system
CN102869384B (zh) 2009-06-22 2016-01-13 伯纳姆医学研究所 使用带有c-端元件的肽和蛋白质的方法和组合物
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
WO2012118778A1 (fr) 2011-02-28 2012-09-07 Sanford-Burnham Medical Research Institute Peptides car tronqués, procédés et compositions les utilisant
US9200251B1 (en) 2011-03-31 2015-12-01 David Gordon Bermudes Bacterial methionine analogue and methionine synthesis inhibitor anticancer, antiinfective and coronary heart disease protective microcins and methods of treatment therewith
CN102604949A (zh) * 2011-04-12 2012-07-25 南京大学 一种乙醇脱氢酶启动子驱动的厌氧组织选择性基因表达方法及应用
AU2012262488A1 (en) 2011-05-31 2014-01-16 Airware, Inc. Re-calibration of AB NDIR gas sensors
US10179801B2 (en) 2011-08-26 2019-01-15 Sanford-Burnham Medical Research Institute Truncated LYP-1 peptides and methods and compositions using truncated LYP-1 peptides
US9593339B1 (en) 2013-02-14 2017-03-14 David Gordon Bermudes Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment
GB201308742D0 (en) * 2013-05-15 2013-06-26 Imp Innovations Bacteriophage
WO2015002939A1 (fr) * 2013-07-01 2015-01-08 Massachusetts Institute Of Technology Fonctionnalisation de bactéries endogènes
US9737592B1 (en) 2014-02-14 2017-08-22 David Gordon Bermudes Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
GB201416788D0 (en) * 2014-09-23 2014-11-05 Univ Glasgow Therapeutic applications for pyocins
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
BR112018010737A2 (pt) 2015-11-25 2018-11-27 Universidad De Los Andes composição compreendendo bacteriófagos para reduzir, eliminar e/ou prevenir a salmonella enteritidis, salmonella typhimurium e salmonella paratyphi b
US11473104B2 (en) * 2015-12-04 2022-10-18 Massachusetts Institute Of Technology Engineered phagemids
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
WO2018204392A1 (fr) 2017-05-02 2018-11-08 Stanford Burnham Prebys Medical Discovery Institute Peptide liant des monocytes/macrophages associés à une tumeur et procédés d'utilisation associés
US20220119450A1 (en) 2019-02-04 2022-04-21 University Of Tartu Bi-specific extracellular matrix binding peptides and methods of use thereof
US11471497B1 (en) 2019-03-13 2022-10-18 David Gordon Bermudes Copper chelation therapeutics
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999010014A2 (fr) * 1997-08-29 1999-03-04 Selective Genetics, Inc. Administration de gene effectuee au moyen de recepteurs, et utilisant des vecteurs bacteriophages

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001014579A2 (fr) * 1999-08-26 2001-03-01 Vion Pharmaceuticals, Inc. Compositions et procedes pour la delivrance d'un agent par le biais d'une salmonelle attenuee contenant un phage

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999010014A2 (fr) * 1997-08-29 1999-03-04 Selective Genetics, Inc. Administration de gene effectuee au moyen de recepteurs, et utilisant des vecteurs bacteriophages

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
LOW ET AL.: "Lipid a mutant salmonella with suppressed virulence and TNFalpha induction retain tumor-targeting in vivo", NATURE BIOTECHNOLOGY, vol. 17, January 1999 (1999-01-01), pages 37 - 41, XP002939098 *
LOW ET AL.: "Tumor-targeted salmonella as a novel anti-cancer vector", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, vol. 38, no. 2301, 12 April 1997 (1997-04-12) - 16 April 1997 (1997-04-16), pages 343, XP002939301 *
PAGLIA ET AL.: "Gene transfer in dendritic cells, induced by oral DNA vaccination with salmonella typhimurium in protective immunity against a murine fibrosarcoma", BLOOD, vol. 92, no. 9, 1 November 1998 (1998-11-01), pages 3172 - 3176, XP002939097 *
PAWELEK ET AL.: "Tumor-targeted salmonella as a novel anticancer vector", CANCER RESEARCH, vol. 57, 15 October 1997 (1997-10-15), pages 4537 - 4544, XP002939099 *
SALTZMAN ET AL.: "Antitumor mechanisms of attenuated salmonella typhimurium containing the gene for human interleukin-2: A novel antitumor agent", J. PEDIATRIC SURGERY, vol. 32, no. 2, February 1997 (1997-02-01), pages 301 - 306, XP002939100 *

Also Published As

Publication number Publication date
US20040219169A1 (en) 2004-11-04
WO2001014579A9 (fr) 2002-09-19
US20030113293A1 (en) 2003-06-19
AU7572900A (en) 2001-03-19
WO2001014579A2 (fr) 2001-03-01
CA2381755A1 (fr) 2001-03-01

Similar Documents

Publication Publication Date Title
WO2001014579A3 (fr) Compositions et procedes pour la delivrance d'un agent par le biais d'une salmonelle attenuee contenant un phage
HUP0303296A3 (en) Carboxamide derivatives and their use in the treatment of thromboembolic diseases and tumours, process for their preparation and pharmaceutical compositions containing them
AU2001254624A1 (en) Human coagulation factor vii variants
EP1352896A3 (fr) Dérivés d'adamantane pour le traitment de maladies inflammatoires, immunes et cardiovasculaire
EP0873141A4 (fr) Compositions et methodes a usage therapeutique
WO2002049590A3 (fr) Produits antisudorifiques
HUP0400231A3 (en) Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer
WO2001001748A3 (fr) Composés se liant à her2
WO1999058552A3 (fr) Utilisation d'analogues d'acides gras non beta-oxydables pour traiter les etats lies au syndrome x
SG146648A1 (en) Pharmaceutical compositions for treating premature ejaculation by pulmonary inhalation
WO2003070283A3 (fr) Agent inhibant l'evolution ou la progression des maladies proliferatives, en particulier des cancers, et composition pharmaceutique contenant ledit agent
WO2002004514A3 (fr) Compositions et procedes pour le traitement et le diagnostic du cancer du poumon
EP1262177A3 (fr) Utilisation médicale des composés thyromimétiques pour traiter la chute des cheveux et compositions
AU4871797A (en) Magnesium (-)hydroxycitrate, preparation process, uses and compositions, in particular pharmaceutical compositions, containing it
TW200407425A (en) Human coagulation factor VII polypeptides
WO2002056708A3 (fr) Preparation destinee a ameliorer l'assimilation des aliments
HK1036630A1 (en) Peptides based on the sequence of human lactoferrin and their use
WO2002070464A3 (fr) Nouvelles hydrazones
MXPA02012249A (es) Peptidos, composiciones y metodos para el tratamiento de burkholderia cepacia.
HUP0204243A2 (hu) Új Helicobacter pylori-kötő anyagok, és alkalmazásuk
HUP0302538A3 (en) 3,7-diazabicyclo[3.3.0]oczanes and their use in the treatment of cardiac arrhythmias, process for their preparation and pharmaceutical compositions containing them
EP1613345A4 (fr) Compositions contenant un virus syncytial respiratoire de la souche 9320 du sous-groupe b, et procedes associes
HK1041219A1 (en) Mucosal delivery system
AU1815899A (en) Method and composition to enhance the efficacy of a vaccine using chemokines
ATE293991T1 (de) VERWENDUNG EINES MIT DEM PEPTID ßELAGIGILTVß ASSOZIIERTEN ENTEROBAKTERIEN-PROTEINS OMPA ZUR BEHANDLUNG VON MELANOMEN

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2381755

Country of ref document: CA

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

AK Designated states

Kind code of ref document: C2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/7-7/7, DRAWINGS, REPLACED BY NEW PAGES 1/7-7/7; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP